APVO · Aptevo Therapeutics Inc. · Executive Compensation
$0.40
-0.01 (-3.36%)
At close · Nov 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 16, 2026
Substantial doubt about the company's ability to continue as a going concern.
“When considered in aggregate, these factors raise substantial doubt about our ability to continue as a going concern for the one-year period from the date of issuance of these financial statements.”View the 10-Q filed Nov 16, 2026
Market Cap
$1.43M
Shares
3.46M
Volume · Nov 20
95.64K
Avg daily vol (3M)
130.94K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Marvin L. White | President and Chief Executive Officer | $1,277,403 |
| Jeffrey G. Lamothe | Executive Vice President and Chief Operating Officer | $1,020,205 |
| SoYoung Kwon | Senior Vice President, General Counsel, Business Development and Corporate Affairs | $904,464 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Marvin L. White | Chief Executive Officer and President | $974,052 |
| Jeffrey G. Lamothe | Senior Vice President and Chief Financial Officer | $641,192 |
| Jane Gross | Senior Vice President and Chief Scientific Officer | $587,949 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Marvin L. White | Chief Executive Officer and President | $1,104,819 |
| Jeffrey G. Lamothe | Senior Vice President and Chief Financial Officer | $691,987 |
| Jane Gross | Senior Vice President and Chief Scientific Officer | $636,446 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| John E. Niederhuber | Lead Independent Director | Appointed | 2026-02-03 |
| Jeff Lamothe | Class III director | Appointed | 2026-02-03 |
| Jeff Lamothe | President and Chief Executive Officer | Appointed | 2026-02-03 |
| Marvin L. White | Executive Chair of the Board | Appointed | 2026-02-03 |
|
Marvin L. White
“Mr. White’s intention to resign was not because of any disagreement with management or the Board of Directors of the Company (the “Board”) on any matter relating to the Company’s operations, policies or practices.”
|
President and Chief Executive Officer | Retired | 2026-02-03 |
| Daphne Taylor | Senior Vice President, Chief Financial Officer | Appointed | 2023-03-07 |
| Jeffrey G. Lamothe | Executive Vice President, Chief Operating Officer | Appointed | 2023-03-07 |
| John Niederhuber, M.D. | Chairman of the Board | Appointed | 2022-01-21 |
| Jane Gross | Chief Scientific Officer | Resigned | 2021-08-27 |
Leadership
- Barbara Lopez Kunz CEO, Board Member
- Daniel J. Abdun-Nabi CEO, Board Member
- Jeff Lamothe CEO, Board Member
- Jeffrey G. Lamothe CEO, COO
- Zsolt Harsanyi CEO, Board Member
- John E. Niederhuber Chairman, Board Member
- John Niederhuber, M.D. Chairman
- Marvin L. White Chairman, Board Member
- Daphne Taylor CFO
- SoYoung Kwon General Counsel
- Grady Grant Board Member
Key facts
CIK
1671584
CUSIP
03835L702
13F (30d)
14 filings
12 filers
Visit website
Investor relations